FOXFIRE Global Study Completes Patient Recruitment

Thursday 08 January 2015
Sirtex Medical Limited (ASX:SRX) is pleased to announce the completion of patient recruitment in the FOXFIRE Global randomised controlled clinical study comparing SIR-Spheres®Y-90 resin microspheres in combination with standard of care chemotherapy versus chemotherapy alone in first - line metastatic colorectal cancer (mCRC)in patients with inoperable liver metastases.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage